Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 414

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Open access
Westendorf, Kathryn, Žentelis, Stefanie, Wang, Lingshu, Foster, Denisa, Vaillancourt, Peter, Wiggin, Matthew, Lovett, Erica, van der Lee, Robin, Hendle, Jörg, Pustilnik, Anna, Sauder, J. Michael, Kraft, Lucas, Hwang, Yuri, Siegel, Robert W., Chen, Jinbiao, Heinz, Beverly A., Higgs, Richard E., Kallewaard, Nicole L., Jepson, Kevin, Goya, Rodrigo, Smith, Maia A., Collins, David W., Pellacani, Davide, Xiang, Ping, de Puyraimond, Valentine, Ricicova, Marketa, Devorkin, Lindsay, Pritchard, Caitlin, O’Neill, Aoise, Dalal, Kush, Panwar, Pankaj, Dhupar, Harveer, Garces, Fabian A., Cohen, Courtney A., Dye, John M., Huie, Kathleen E., Badger, Catherine V., Kobasa, Darwyn, Audet, Jonathan, Freitas, Joshua J., Hassanali, Saleema, Hughes, Ina, Munoz, Luis, Palma, Holly C., Ramamurthy, Bharathi, Cross, Robert W., Geisbert, Thomas W., Menachery, Vineet, Lokugamage, Kumari, Borisevich, Viktoriya, Lanz, Iliana, Anderson, Lisa, Sipahimalani, Payal, Corbett, Kizzmekia S., Yang, Eun Sung, Zhang, Yi, Shi, Wei, Zhou, Tongqing, Choe, Misook, Misasi, John, Kwong, Peter D., Sullivan, Nancy J., Graham, Barney S., Fernandez, Tara L., Hansen, Carl L., Falconer, Ester, Mascola, John R., Jones, Bryan E., Barnhart, Bryan C.·2022·Cell Reports
DOI 10.1016/j.celrep.2022.110812

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody. LY-CoV1404 potently neutralizes authentic SARS-CoV-2, B.1.1.7, B.1.351, and B.1.617.2. In pseudovirus neutralization studies, LY-CoV1404 potently neutralizes variants, including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, B.1.1.529, and the BA.2 subvariant. Structural analysis reveals that the contact residues of the LY-CoV1404 epitope are highly conserved, except for N439 and N501. The binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The broad and potent neutralization activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2022.110812

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Research works printed but not linked: 3

  1. Jones, 2020, LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection, bioRxiv
  2. Lieu, 2020, Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing, Plos One, 15, e0232311, 10.1371/journal.pone.0232311 · DOI
  3. Yao, 2021, Spike mutations decrease SARS-CoV-2 sensitivity to neutralizing antibodies but not ACE2-Ig in vitro, bioRxiv

Cited by

See all 414

Metadata

Authors
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., Sauder, J. M., Kraft, L., Hwang, Y., Siegel, R. W., Chen, J., Heinz, B. A., Higgs, R. E., Kallewaard, N. L., Jepson, K., Goya, R., Smith, M. A., Collins, D. W., Pellacani, D., Xiang, P., de Puyraimond, V., Ricicova, M., Devorkin, L., Pritchard, C., O’Neill, A., Dalal, K., Panwar, P., Dhupar, H., Garces, F. A., Cohen, C. A., Dye, J. M., Huie, K. E., Badger, C. V., Kobasa, D., Audet, J., Freitas, J. J., Hassanali, S., Hughes, I., Munoz, L., Palma, H. C., Ramamurthy, B., Cross, R. W., Geisbert, T. W., Menachery, V., Lokugamage, K., Borisevich, V., Lanz, I., Anderson, L., Sipahimalani, P., Corbett, K. S., Yang, E. S., Zhang, Y., Shi, W., Zhou, T., Choe, M., Misasi, J., Kwong, P. D., Sullivan, N. J., Graham, B. S., Fernandez, T. L., Hansen, C. L., Falconer, E., Mascola, J. R., Jones, B. E., & Barnhart, B. C.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2022-05
Volume
39
Issue
7
Pages
110812
ISSN
2211-1247 (ISSN-L)
DOI
10.1016/j.celrep.2022.110812
OpenAlex
W4225647476
Cited by
414
References
64
FWCI
44.23
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Argonne National Laboratory (DE-AC02-06CH11357)
  • U.S. Department of Energy
  • Defense Advanced Research Projects Agency Defense Sciences Office (D18AC00002)
  • National Institute of Allergy and Infectious Diseases
  • University of Texas Medical Branch
  • Defense Advanced Research Projects Agency
  • Horizon 2020 Framework Programme
  • Eli Lilly and Company
  • Vaccine Research Center
  • Office of Science
  • U.S. Department of Defense
  • Horizon 2020 (653316)
  • National Institutes of Health (UC7AI094660)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. https://app.cochat.ai/papers/10.1016/j.celrep.2022.110812
The paper
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., Sauder, J. M., Kraft, L., Hwang, Y., Siegel, R. W., Chen, J., Heinz, B. A., Higgs, R. E., Kallewaard, N. L., Jepson, K., . . . Barnhart, B. C. (2022). LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports. https://doi.org/10.1016/j.celrep.2022.110812

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.